ROCKVILLE, Md.--(BUSINESS WIRE)--June 14, 2007--Emergent
BioSolutions Inc. (NYSE:EBS), a biopharmaceutical company, announced
today the results of the company's 2007 annual meeting of
stockholders, which took place today at the Hyatt Regency Bethesda at
10:00 am Eastern.
There were present, in person or represented by proxy, the holders
of more than a majority of the shares of the outstanding common stock
of the company, thus constituting a quorum.
Proposal 1--Election of Directors
The following individuals were elected Class I directors of the
company to serve for a three-year term expiring 2010: Fuad El-Hibri,
Jerome M. Hauer and Ronald B. Richard.
Proposal 2--Ratify Selection of Ernst & Young LLP as the Company's
Independent Registered Public Accounting Firm
The proposal to select Ernst & Young LLP as the company's
independent registered public accounting firm for the fiscal year
ending December 31, 2007 successfully passed.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a biopharmaceutical company
dedicated to one simple mission--to protect life. We develop,
manufacture and commercialize immunobiotics, consisting of vaccines
and therapeutics that assist the body's immune system to prevent or
treat disease. Our biodefense business focuses on immunobiotics for
use against biological agents that are potential weapons of
bioterrorism and biowarfare. Our marketed product, BioThrax(R)
(Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S.
Food and Drug Administration for the prevention of anthrax infection.
Our commercial business focuses on immunobiotics for use against
infectious diseases and other medical conditions that have resulted in
significant unmet or underserved public health needs. More information
on the company is available at www.emergentbiosolutions.com.
CONTACT: Emergent BioSolutions Inc.
Robert G. Burrows
Vice President, Investor Relations
SOURCE: Emergent BioSolutions Inc.